Media Relations
If you are a journalist with a question about Lundbeck or would like to request an interview, please contact Media Relations – and we will get back to you. Please note this service is for journalists and other media professionals only. Please kindly note all other requests to this e-mail will not receive a response.
Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases.
Brain disorders affect a large part of the world’s population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments.
As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology.
We are committed to fighting stigma and we act to improve health equity. We strive to create long-term value for our shareholders by making a positive contribution to patients, their families and society as a whole.
Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com/global and connect with us via LinkedIn.
Facts about Lundbeck
70+
Years in the forefront of neuroscience research
100+
Countries of operation around the world
5,300+
Employees worldwide
24b DKK
Of revenue generated in 2025